               SEQUENCE LISTING

<110> INSERM

<120> MONOCLONAL ANTIBODIES BINDING TO THE CD160 TRANSMEMBRANE ISOFORM

<130> BIO16355 BENSUSSAN / MC

<160> 32

<170> BiSSAP 1.3.6

<210> 1
<211> 234
<212> PRT
<213> Artificial Sequence


<220> 
<223> CD160 transmembrane isoform

<300> 
<301> Giustiniani J., Bensussan A., Marie-Cardine A.
<302> Identification and characterization of a transmembrane isoform of
       Identification and characterization of a transmembrane isoform o
      f CD160 (CD160-TM), a unique activating receptor selectively Iden
      tification and characterization of a transmembrane isoform of Ide
<303> J Immunol
<304> 182
<305> 1
<306> 63-71
<307> 2009

<300> 
<310> WO2008155363
<311> 18/06/2008
<312> 24/12/2008

<400> 1
Met Leu Leu Glu Pro Gly Arg Gly Cys Cys Ala Leu Ala Ile Leu Leu 
1               5                   10                  15      
Ala Ile Val Asp Ile Gln Ser Gly Gly Cys Ile Asn Ile Thr Ser Ser 
            20                  25                  30          
Ala Ser Gln Glu Gly Thr Arg Leu Asn Leu Ile Cys Thr Val Trp His 
        35                  40                  45              
Lys Lys Glu Glu Ala Glu Gly Phe Val Val Phe Leu Cys Lys Asp Arg 
    50                  55                  60                  
Ser Gly Asp Cys Ser Pro Glu Thr Ser Leu Lys Gln Leu Arg Leu Lys 
65                  70                  75                  80  
Arg Asp Pro Gly Ile Asp Gly Val Gly Glu Ile Ser Ser Gln Leu Met 
                85                  90                  95      
Phe Thr Ile Ser Gln Val Thr Pro Leu His Ser Gly Thr Tyr Gln Cys 
            100                 105                 110         
Cys Ala Arg Ser Gln Lys Ser Gly Ile Arg Leu Gln Gly His Phe Phe 
        115                 120                 125             
Ser Ile Leu Phe Thr Glu Thr Gly Asn Tyr Thr Val Thr Gly Leu Lys 
    130                 135                 140                 
Gln Arg Gln His Leu Glu Phe Ser His Asn Glu Gly Thr Leu Ser Ser 
145                 150                 155                 160 
Gly Phe Leu Gln Glu Lys Val Trp Val Met Leu Val Thr Ser Leu Val 
                165                 170                 175     
Ala Leu Gln Gly Met Ser Lys Arg Ala Val Ser Thr Pro Ser Asn Glu 
            180                 185                 190         
Gly Ala Ile Ile Phe Leu Pro Pro Trp Leu Phe Ser Arg Arg Arg Arg 
        195                 200                 205             
Leu Glu Arg Met Ser Arg Gly Arg Glu Lys Cys Tyr Ser Ser Pro Gly 
    210                 215                 220                 
Tyr Pro Gln Glu Ser Ser Asn Gln Phe His 
225                 230                 

<210> 2
<211> 160
<212> PRT
<213> Artificial Sequence


<220> 
<223> CD160 GPI-anchored isoform

<300> 
<301> Nikolova M., Marie-Cardine A., Boumsell L., Bensussan A.
<302> BY55/CD160 acts as a co-receptor in TCR signal transduction of a
      BY55/CD160 acts as a co-receptor in TCR signal transduction of a
      human circulating cytotoxic effector T lymphocyte subset lacking
      BY55/CD160 acts as a co-receptor in TCR signal transduction of a
<303> Int Immunol.
<304> 14
<305> 5
<306> 445-51
<307> 2002

<300> 
<310> WO2006015886
<311> 09/08/2005
<312> 16/02/2006

<400> 2
Met Leu Leu Glu Pro Gly Arg Gly Cys Cys Ala Leu Ala Ile Leu Leu 
1               5                   10                  15      
Ala Ile Val Asp Ile Gln Ser Gly Gly Cys Ile Asn Ile Thr Ser Ser 
            20                  25                  30          
Ala Ser Gln Glu Gly Thr Arg Leu Asn Leu Ile Cys Thr Val Trp His 
        35                  40                  45              
Lys Lys Glu Glu Ala Glu Gly Phe Val Val Phe Leu Cys Lys Asp Arg 
    50                  55                  60                  
Ser Gly Asp Cys Ser Pro Glu Thr Ser Leu Lys Gln Leu Arg Leu Lys 
65                  70                  75                  80  
Arg Asp Pro Gly Ile Asp Gly Val Gly Glu Ile Ser Ser Gln Leu Met 
                85                  90                  95      
Phe Thr Ile Ser Gln Val Thr Pro Leu His Ser Gly Thr Tyr Gln Cys 
            100                 105                 110         
Cys Ala Arg Ser Gln Lys Ser Gly Ile Arg Leu Gln Gly His Phe Phe 
        115                 120                 125             
Ser Ile Leu Phe Thr Glu Thr Gly Asn Tyr Thr Val Thr Gly Leu Lys 
    130                 135                 140                 
Gln Arg Gln His Leu Glu Phe Ser His Asn Glu Gly Thr Leu Ser Ser 
145                 150                 155                 160 



<210> 3
<211> 160
<212> PRT
<213> Artificial Sequence


<220> 
<223> CD160 soluble isoform

<300> 
<301> Giustiniani J., Marie-Cardine A., Bensussan A.
<302> A soluble form of the MHC class I-specific CD160 receptor is A so
      luble form of the MHC class I-specific CD160 receptor is released
       from human activated NK lymphocytes and inhibits A soluble form 
      of the MHC class I-specific CD160 receptor is A soluble form of t
<303> J Immunol.
<304> 178
<305> 3
<306> 1293-300
<307> 2007

<400> 3
Met Leu Leu Glu Pro Gly Arg Gly Cys Cys Ala Leu Ala Ile Leu Leu 
1               5                   10                  15      
Ala Ile Val Asp Ile Gln Ser Gly Gly Cys Ile Asn Ile Thr Ser Ser 
            20                  25                  30          
Ala Ser Gln Glu Gly Thr Arg Leu Asn Leu Ile Cys Thr Val Trp His 
        35                  40                  45              
Lys Lys Glu Glu Ala Glu Gly Phe Val Val Phe Leu Cys Lys Asp Arg 
    50                  55                  60                  
Ser Gly Asp Cys Ser Pro Glu Thr Ser Leu Lys Gln Leu Arg Leu Lys 
65                  70                  75                  80  
Arg Asp Pro Gly Ile Asp Gly Val Gly Glu Ile Ser Ser Gln Leu Met 
                85                  90                  95      
Phe Thr Ile Ser Gln Val Thr Pro Leu His Ser Gly Thr Tyr Gln Cys 
            100                 105                 110         
Cys Ala Arg Ser Gln Lys Ser Gly Ile Arg Leu Gln Gly His Phe Phe 
        115                 120                 125             
Ser Ile Leu Phe Thr Glu Thr Gly Asn Tyr Thr Val Thr Gly Leu Lys 
    130                 135                 140                 
Gln Arg Gln His Leu Glu Phe Ser His Asn Glu Gly Thr Leu Ser Ser 
145                 150                 155                 160 



<210> 4
<211> 24
<212> PRT
<213> Artificial Sequence


<220> 
<223> Epitope

<400> 4
Lys Asp Arg Ser Gly Asp Cys Ser Pro Glu Thr Ser Leu Lys Gln Leu 
1               5                   10                  15      
Arg Leu Lys Arg Asp Pro Gly Ile 
            20                  

<210> 5
<211> 15
<212> PRT
<213> Artificial Sequence


<220> 
<223> Epitope

<400> 5
Leu Val Ala Leu Gln Gly Met Ser Lys Arg Ala Val Ser Thr Pro 
1               5                   10                  15  

<210> 6
<211> 14
<212> PRT
<213> Artificial Sequence


<220> 
<223> VL-CDR1

<220> 
<221> SITE
<222> 11
<223> X is Y or S

<220> 
<221> SITE
<222> 12
<223> X is G or Y

<400> 6
Ala Gly Thr Ser Ser Asp Val Gly Gly Tyr Xaa Xaa Val Ser 
1               5                   10                  

<210> 7
<211> 7
<212> PRT
<213> Artificial Sequence


<220> 
<223> VL-CDR2

<400> 7
Tyr Asp Ser Tyr Arg Pro Ser 
1               5           

<210> 8
<211> 10
<212> PRT
<213> Artificial Sequence


<220> 
<223> VL-CDR3

<220> 
<221> SITE
<222> 3
<223> X is S or Y

<400> 8
Ser Ser Xaa Thr Tyr Tyr Ser Thr Arg Val 
1               5                   10  

<210> 9
<211> 5
<212> PRT
<213> Artificial Sequence


<220> 
<223> VH-CDR1

<220> 
<221> SITE
<222> 3
<223> X is S or Y

<400> 9
Asn Tyr Xaa Met Asn 
1               5   

<210> 10
<211> 17
<212> PRT
<213> Artificial Sequence


<220> 
<221> SITE
<222> 1
<223> X is Y or G

<220> 
<223> VH-CDR2

<220> 
<221> SITE
<222> 10
<223> X is N or S

<400> 10
Xaa Ile Tyr Gly Ser Ser Arg Tyr Ile Xaa Tyr Ala Asp Phe Val Lys 
1               5                   10                  15      
Gly 
    

<210> 11
<211> 4
<212> PRT
<213> Artificial Sequence


<220> 
<223> VH-CDR3

<400> 11
Gly Met Asp Val 
1               

<210> 12
<211> 117
<212> PRT
<213> Artificial Sequence


<220> 
<223> VH region of A12 antibody

<400> 12
Glu Val Gln Leu Val Glu Ser Gly Gly Ser Leu Val Lys Pro Gly Gly 
1               5                   10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 
            20                  25                  30          
Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              
Ser Tyr Ile Tyr Gly Ser Ser Arg Tyr Ile Ser Tyr Ala Asp Phe Val 
    50                  55                  60                  
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Thr Asn Ser Leu Tyr 
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      
Val Arg Ser Tyr Tyr Gly Gly Met Asp Val Trp Gly Arg Gly Thr Leu 
            100                 105                 110         
Val Thr Val Ser Ser 
        115         

<210> 13
<211> 109
<212> PRT
<213> Artificial Sequence


<220> 
<223> VL region of A12 antibody

<400> 13
Gln Ser Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 
1               5                   10                  15      
Ser Ile Thr Ile Ser Cys Ala Gly Thr Ser Ser Asp Val Gly Gly Tyr 
            20                  25                  30          
Tyr Gly Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 
        35                  40                  45              
Met Ile Tyr Tyr Asp Ser Tyr Arg Pro Ser Gly Val Ser Asn Arg Phe 
    50                  55                  60                  
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 
65                  70                  75                  80  
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Ser Thr Tyr Tyr 
                85                  90                  95      
Ser Thr Arg Val Phe Gly Gly Gly Thr Lys Leu Glu Lys 
            100                 105                 

<210> 14
<211> 117
<212> PRT
<213> Artificial Sequence


<220> 
<223> VH region of B6 antibody

<400> 14
Glu Val Gln Leu Val Glu Ser Gly Gly Ser Leu Val Lys Pro Gly Gly 
1               5                   10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 
            20                  25                  30          
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              
Ser Gly Ile Tyr Gly Ser Ser Arg Tyr Ile Asn Tyr Ala Asp Phe Val 
    50                  55                  60                  
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Thr Asn Ser Leu Tyr 
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      
Val Arg Ser Tyr Tyr Gly Gly Met Asp Val Trp Gly Arg Gly Thr Leu 
            100                 105                 110         
Val Thr Val Ser Ser 
        115         

<210> 15
<211> 109
<212> PRT
<213> Artificial Sequence


<220> 
<223> VL region of B6 antibody

<400> 15
Gln Ser Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 
1               5                   10                  15      
Ser Ile Thr Ile Ser Cys Ala Gly Thr Ser Ser Asp Val Gly Gly Tyr 
            20                  25                  30          
Ser Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 
        35                  40                  45              
Met Ile Tyr Tyr Asp Ser Tyr Arg Pro Ser Gly Val Ser Asn Arg Phe 
    50                  55                  60                  
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 
65                  70                  75                  80  
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Tyr Tyr 
                85                  90                  95      
Ser Thr Arg Val Phe Gly Gly Gly Thr Lys Leu Glu Lys 
            100                 105                 

<210> 16
<211> 345
<212> DNA
<213> Artificial Sequence


<220> 
<223> VH region of A12 antibody

<400> 16
aggtgcagct ggtggagtct gggggaagcc tggtcaagcc tggggggtcc ctgagactct      60

cctgtgcagc tctggattca ccttcagtaa ctatagtatg aactgggtcc gccaggctcc     120

agggaagggc tggagtggat ctcatatatt tatggtagta gtagatatat aagttacgca     180

gacttcgtga agggcgattc accatctcca gagacaacgc cacgaactca ctgtacctgc     240

aaatgaacag cctagagccg aggacacggc tgtttattac tgtgtgagat cctattatgg     300

cggtatggac gtctggggca gggcaccctg gtcaccgtct cctca                     345


<210> 17
<211> 325
<212> DNA
<213> Artificial Sequence


<220> 
<223> VL region of A12 antibody

<400> 17
cagtctgtgc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc      60

tcctgcgctg aaccagcagt gacgttggtg gttattatgg cgtctcctgg taccaacaac     120

acccaggaaa gcccccaaac tcatgattta ttatgacagt tatcggccct caggggtttc     180

taatcgcttc tctggcccaa gtctggcaac acggcctccc tgacaatctc tgggctccag     240

gctgaggacg aggcgattat tactgcagct caagtacata ttatagcact cgagttttcg     300

gcggagggac caagctggag ataaa                                           325


<210> 18
<211> 354
<212> DNA
<213> Artificial Sequence


<220> 
<223> VH region of B6 antibody

<400> 18
gaggtgcagc tggtggagtc tgggggaagc ctggtcaagc ctggggggtc cctgagactc      60

tcctgtgcag cctctggatt caccttcagt aactattata tgaactgggt ccgccaggct     120

ccagggaagg ggctggagtg gatctcaggc atttatggta gtagtagata tataaactac     180

gcagacttcg tgaagggccg attcaccatc tccagagaca acgccacgaa ctcactgtac     240

ctgcaaatga acagcctgag agccgaggac acggctgttt attactgtgt gagatccagt     300

ggctatggcg gtatggacgt ctggggcaga ggcaccctgg tcaccgtctc ctca           354


<210> 19
<211> 330
<212> DNA
<213> Artificial Sequence


<220> 
<223> VL region of B6 antibody

<400> 19
cagtctgtgc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc      60

tcctgcgctg gaaccagcag tgacgttggt ggttatagtt atgtctcctg gtaccaacaa     120

cacccaggca aagcccccaa actcatgatt tattatgaca gttatcggcc ctcaggggtt     180

tctaatcgct tctctggctc caagtctggc aacacggcct ccctgacaat ctctgggctc     240

caggctgagg acgaggctga ttattactgc agctcatata catattatag cactcgagtt     300

ttcggcggag ggaccaagct ggagatcaaa                                      330


<210> 20
<211> 14
<212> PRT
<213> Artificial Sequence


<220> 
<223> VL-CDR1

<400> 20
Ala Gly Thr Ser Ser Asp Val Gly Gly Tyr Tyr Gly Val Ser 
1               5                   10                  

<210> 21
<211> 14
<212> PRT
<213> Artificial Sequence


<220> 
<223> VL-CDR1

<400> 21
Ala Gly Thr Ser Ser Asp Val Gly Gly Tyr Tyr Tyr Val Ser 
1               5                   10                  

<210> 22
<211> 14
<212> PRT
<213> Artificial Sequence


<220> 
<223> VL-CDR1

<400> 22
Ala Gly Thr Ser Ser Asp Val Gly Gly Tyr Ser Gly Val Ser 
1               5                   10                  

<210> 23
<211> 14
<212> PRT
<213> Artificial Sequence


<220> 
<223> VL-CDR1

<400> 23
Ala Gly Thr Ser Ser Asp Val Gly Gly Tyr Ser Tyr Val Ser 
1               5                   10                  

<210> 24
<211> 10
<212> PRT
<213> Artificial Sequence


<220> 
<223> VL-CDR3

<400> 24
Ser Ser Ser Thr Tyr Tyr Ser Thr Arg Val 
1               5                   10  

<210> 25
<211> 10
<212> PRT
<213> Artificial Sequence


<220> 
<223> VL-CDR3

<400> 25
Ser Ser Tyr Thr Tyr Tyr Ser Thr Arg Val 
1               5                   10  

<210> 26
<211> 5
<212> PRT
<213> Artificial Sequence


<220> 
<223> VH-CDR1

<400> 26
Asn Tyr Ser Met Asn 
1               5   

<210> 27
<211> 5
<212> PRT
<213> Artificial Sequence


<220> 
<223> VH-CDR1

<400> 27
Asn Tyr Tyr Met Asn 
1               5   

<210> 28
<211> 17
<212> PRT
<213> Artificial Sequence


<220> 
<223> VH-CDR2

<400> 28
Tyr Ile Tyr Gly Ser Ser Arg Tyr Ile Asn Tyr Ala Asp Phe Val Lys 
1               5                   10                  15      
Gly 
    

<210> 29
<211> 17
<212> PRT
<213> Artificial Sequence


<220> 
<223> VH-CDR2

<400> 29
Tyr Ile Tyr Gly Ser Ser Arg Tyr Ile Ser Tyr Ala Asp Phe Val Lys 
1               5                   10                  15      
Gly 
    

<210> 30
<211> 17
<212> PRT
<213> Artificial Sequence


<220> 
<223> VH-CDR2

<400> 30
Gly Ile Tyr Gly Ser Ser Arg Tyr Ile Asn Tyr Ala Asp Phe Val Lys 
1               5                   10                  15      
Gly 
    

<210> 31
<211> 17
<212> PRT
<213> Artificial Sequence


<220> 
<223> VH-CDR2

<400> 31
Gly Ile Tyr Gly Ser Ser Arg Tyr Ile Ser Tyr Ala Asp Phe Val Lys 
1               5                   10                  15      
Gly 
    

<210> 32
<211> 16
<212> PRT
<213> Artificial Sequence


<220> 
<223> Peptide 2 - amino acids 144-158 of CD160-TM

<300> 
<310> WO2008155363
<311> 18/06/2008
<312> 24/12/2008

<400> 32
Lys Gln Arg Gln His Leu Glu Phe Ser His Asn Asn Glu Gly Thr Leu 
1               5                   10                  15      



